Co-diagnostics CODX 深 滬
已收盤 08-07 16:00:00 美东时间
1.52
+0.100
+7.04%
華盛通- 最 高1.54
- 今 開1.45
- 成交量 24.93万股
- 最 低 1.39
- 昨 收 1.42
- 總市值 802.40万
- 52周最高 13.54
- 市盈率 靜 --
- 換手率 4.72%
- 52周最低 1.26
- 委 比 27.75%
- 總股本 527.90万
- 歷史最高 13.54
- 量 比 0.63
- 振 幅 10.56%
- 歷史最低 1.26
- 每 手 1
- 風險率 1.73%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Co-Diagnostics Submits FDA 510(k) Premarket Notification for Upper Respiratory Point-of-Care Test
Submission includes a concurrent CLIA Waiver by Application for use of the test on the Co-Dx PCR Pro® instrument in decentralized point-of-care settings SALT LAKE CITY, Aug. 6, 2026 /PRNewsw...
08-06 21:30
Co-Diagnostics Amends Equity Distribution, Extends Issuance Limits
Co-Diagnostics ( ($CODX) ) just unveiled an announcement. On July 27, 2026, Co-...
07-28 05:29
Why Forte Biosciences Shares Are Trading Higher By 39%; Here Are 20 Stocks Moving Premarket
Shares of Forte Biosciences Inc (NASDAQ:FBRX) rose sharply in pre-market trading after argenx SE – ADR (NASDAQ:ARGX) announced plans to acquire the company for $77 per share in cash, valuing the deal at $2.2 billion. Forte Biosciences shares jumped 38.9% to $76.10 in pre-market trading. Here are som...
07-27 17:09
EXCLUSIVE: Co-Diagnostics Marks New Milestone as India TB Test Clinical Studies Begin
Co-Diagnostics Inc. (NASDAQ:CODX) on Wednesday said CoSara Diagnostics Pvt. Ltd, its joint venture in India, is initiating clinical studies for the tuberculosis test on the CoSara PCR Pro instrument. The molecular diagnostics company said the initiation of these clinical studies marks another critic...
07-22 20:46
Co-Diagnostics Vector Smart® Division Expands Footprint to 21 States
Expansion coincides with Co-Dx webinar for prospective mosquito abatement district customers in honor of National Mosquito Control Awareness Week SALT LAKE CITY, June 25, 2026 /PRNewswire/ -...
06-25 21:00
Co-Diagnostics Announces Delegation Visit From CoMira Diagnostics At Co. Headquarters In Salt Lake City; Unveils Future Automated Production Line At Technology, Innovation Event
Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that a delegation from CoMira Diagnostics ("CoMira"), the Company's joint venture with partners in the Ki...
06-18 21:18
Co-Diagnostics Enters Into Exclusive Distribution Agreement With Partner In Mexico For Co-Dx PCR Point-Of-Care Platform
Longstanding distribution partner to support future deployment of Co-Dx™ PCR Pro® and expanding menu of molecular diagnostics products across a key Latin American market SALT LAKE CITY, June 11, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnosti...
06-11 21:05
Co-Diagnostics Advances Dual Ebola PCR Testing Program To Enhance Outbreak Detection And Surveillance In Africa
Dual-assay strategy designed to support outbreak response and surveillance efforts in affected regionsPotential blood-based Ebola assay would represent an important expansion of Co-Dx™ PCR point-of-care platform
06-02 21:09
